MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg/kg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg/m², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.

NCT Number	NCT07331428
Lead Sponsor	Fujian Cancer Hospital
Conditions	Nasopharyngeal Carcinoma, Local Recurrence
Enrollment	25 participants
Start Date	2026-01-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-09